SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ArQule, Inc. (ARQL)
An SI Board Since April 2003
Posts SubjectMarks Bans Symbol
545 40 0 ARQL
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
320I think this is a little weird. I had always figured when it is said relapsed/rkeokalani'nui-1/16/2007
319Your way of making $$ looks very very hard to me. Congrats! (Don't think Ikeokalani'nui-12/8/2006
318OT-Out of SGXP. Thanks again for the tip. Also covered my AVNR. Looks like itkenhott-12/8/2006
317I've been ins and outs and I am just out again. I have made a couple of quakenhott-12/8/2006
316Hard to know what to do. After R walks from the program you still have to worrykeokalani'nui-12/8/2006
315I'm tempted to get back in, now that they're developing some novel compoformer_pgs-12/8/2006
314A million shares traded today. Chart looks strong.keokalani'nui-12/7/2006
313thanks. On the hunt to find solutions. I have found so far a series 2 Supplementlongtermholdings-12/7/2006
312Arqule is all cancer now. Sorry no type 2 diabetes.rkrw-12/6/2006
311Does anyone know if ArQule will or has worked on any solutions for treating serilongtermholdings-12/6/2006
310ArQule Initiates Phase 1 Trial with ARQ 171, Provides Enrollment Update on ARQ 5nigel bates-12/6/2006
309PFE is a johnny-come-lately to the c-met target which is now being featured in trareearth42-12/4/2006
308ArQule Announces Departure of Board Member Nov 21, 2006 16:30:25 (ET) WOBURN,LJM-11/21/2006
307ArQule Announces Encouraging Interim Data from Phase 1 Trial with C-Met Inhibitomopgcw-11/10/2006
306ArQule Announces Data from Phase 1B Trial with ARQ 501 and Docetaxel Thursday Nomopgcw-11/9/2006
305Citation: European Journal of Cancer Supplements, Volume 4, No.12, page 196 L.keokalani'nui-11/7/2006
304I agree, it can certainly get stupid cheap indeed.mopgcw-10/27/2006
303I've started to casually follow arql over the past year, it's reasonablyMike McFarland-10/27/2006
302fwiw, i too am a buyer at 4 or below. it seems a reasonable option value on themopgcw-10/27/2006
301ArQule Announces Third Quarter Fiscal 2006 Results Thursday October 26, 7:12 am mopgcw-10/27/2006
300They will have final data on x501 P1b with docetaxel at eortc, not that there iskeokalani'nui-10/26/2006
299Interesting 10Q today. Note that the company has explicitly reported interim parareearth42-10/26/2006
298anyone hear of this fellow?? ArQule Announces Appointment of Nigel J. Rulewski amopgcw-8/1/2006
297Quiet as a fish's yawn. (ugh. that was bad.)keokalani'nui-7/28/2006
296He is also quiet about the internal programs?kenhott-7/28/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News